Reviewer’s report

Title: Dissemination of Strongyloides stercoralis after initiation of Albendazole: a case report

Version: 1 Date: 2 March 2008

Reviewer: Mark Pietroni

I am familiar with the literature and believe that this case meets one of the 9 criteria for evaluation in the journal: An unexpected event in the course of observing or treating a patient

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: No

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

There is an interesting literature on strogyloides stercoralis hyperinfection syndrome and SLE. I would consider modifying the title and abstract to mention the diagnosis of SLE in this patient.

I think it would help clarity and usefulness to include drug doses in the abstract, especially prednisolone and azathiaprine, but also albendazole and ivermectin.

I find the 1st and 2nd sentences of the 3rd paragraph after the heading 'Case Report' confusing. Taken together they seem to imply that 'albendazole was initiated 20 hours after presentation' and yet also 4 days after admission. This may be a typo (eg should read - after receiving the diagnostic report or similar), a confusion created by a change in institution (?) or even a transatlantic language issue (in the UK presentation means first contact with a doctor and so cannot be after admission).

What next?: Accept after minor revisions
Quality of written English: Acceptable